AbbVie

Open: 143.86 Close: 145.11 Change: 1.25

An AI to read internet: The best strategy to evaluate AbbVie Stock.

Are looking for the most relevant information about AbbVie? Investor spend a lot of time searching for information to make investment decisions in AbbVie. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, company, value, Inc, RINVOQ, approve, Abbvie, and the most common words in the summary are: abbvie, stock, market, price, abbvies, abbv, job, . One of the sentences in the summary was: The company has gained 64% since 2019 primarily due to favorable change in revenues. …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

AbbVie Inc. (ABBV) has been one of the stocks most watched by Zacks.com users lately. The company has gained 64% since 2019 primarily due to favorable change in revenues. RINVOQ (upadacitinib) approved by FDA as the First Bispecific Antibody to Treat Adults with Relapsed or Refractory.

Today's News

AbbVie Inc. (ABBV) stock price, quote & news - stock analysis. Analyst Consensus: Buy Stock Forecasts $164.94 (13.67% upside) AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. The company has gained 64% since 2019 primarily due to favorable change in revenues. Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. deal has transformed its portfolio by lowering its dependence on Humira. AbbVie Inc. (NYSE:ABBV – Get Rating) last released its earnings results on Friday, October 28th. The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 15th. AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. RINVOQ® (upadacitinib) approved by FDA as the First Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma. The Director will lead evaluation of policy and guide the creation of policy recommendations, to ensure a one-AbbVie approach. Abbvie inc. (nyse:abbv) is favoured by institutional owners who hold 71% of the company. Institutional investors commonly compare their own returns to the returns of a commonly followed index. Insiders have been selling lately. AbbVie reported revenues of $12.23 billion in the last reported quarter, representing a year-over-year change of -9.7%. The consensus sales estimate for the current quarter of $13.52 billion indicates a -7.3% change. EPKINLY (epcoritamab-bysp) approved by u.s. fda as the first bispecific antibody to treat adult patients with relapsed or refractory diffuse large b-cell lymphoma (DLBCL) EPKinly is being co-developed by AbbVie and Genmab. FDA approves RINVOQ® (upadacitinib) as a once-daily pill for moderately to severely active crohns disease in adults. RIN VOQ is a selective JAK inhibitor that is being studied in inflammatory diseases. RINVOQ is being co-developed by AbbVie and Genmab as part of the companies oncology collaboration. Risks and uncertainties include, but are not limited to, failure to realize the expected benefits from the acquisition of Allergan. AbbVie will participate in the Bank of America Securities Healthcare Conference on May 9, 2023. European Commission Approval of RINVOQ for the Treatment of Moderately to Severely Active Crohns Disease –  Seventh approved indication. AbbVie Inc. short percent of float has risen 19.44% since its last report. The company has less short interest than most of its peers. The percentage of shares that are sold short for Abbvie has grown. AbbVie Inc generated a negative expected return over the last 90 days. The company currently holds 59.13 B in liabilities with Debt to Equity (D/E) ratio of 4.37, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. AbbVie Inc has return on total asset (ROA) of 0.0944% which means that it generated a profit of $0.09 44 on every $100 spent on assets. AbbVie Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions. Analysts estimate consensus by analysts from Wall Street is used by the market to judge Abbvie Inc. AbbVie Earnings per Share Projection vs Actual Actual Earning per Share of Abbvie refers to what the company shows during its earnings calls or quarterly reports. The higher the earnings per share of Abvie, the better is its profitability. AbbVie stock has received a consensus rating of buy. The market value of Abbvie Inc is measured differently than its book value, which is the value of the company on its balance sheet. The companys book value differs from its market value or its value, called intrinsic value. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohns Disease in Adults. FDA approves Rinvoq for new Crohans disease indication.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

How much time have you spent trying to decide whether investing in AbbVie? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, company, value, Inc, RINVOQ, approve, Abbvie, and the most common words in the summary are: abbvie, stock, market, price, abbvies, abbv, job, . One of the sentences in the summary was: The company has gained 64% since 2019 primarily due to favorable change in revenues. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #stock #market #price #abbvies #abbv #job.